--- title: "Arctic Bioscience Study Strengthens Case for Psoriasis Drug HRO350" type: "News" locale: "en" url: "https://longbridge.com/en/news/279783749.md" description: "Arctic Bioscience AS has announced that new research on herring roe oil has been accepted for publication in the Journal of Lipid Research. The study demonstrates that these compounds enhance the production of mediators relevant to psoriasis, supporting the mechanism of its investigational drug HRO350. This data reinforces the rationale for HRO350's clinical development as a potential oral treatment for mild-to-moderate psoriasis. The research, conducted with UK and Norwegian partners, strengthens Arctic Bioscience's position in inflammation-targeted dermatology and supports its R&D investments." datetime: "2026-03-19T12:06:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279783749.md) - [en](https://longbridge.com/en/news/279783749.md) - [zh-HK](https://longbridge.com/zh-HK/news/279783749.md) generator: "portal-rs" --- # Arctic Bioscience Study Strengthens Case for Psoriasis Drug HRO350 ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Arctic Bioscience AS ( (DE:9TD) ) has provided an update. Arctic Bioscience has reported that new research on herring roe oil and its phospholipid esters has been accepted for publication in the Journal of Lipid Research, underscoring the scientific basis of its marine-derived technologies. The peer-reviewed study shows that these compounds increase production of specialized pro-resolving mediators in human immune and skin cell models relevant to psoriasis, indicating a mechanism by which the company’s investigational drug HRO350 may help resolve inflammation. Company executives say the data provide important mechanistic insight into how HRO350 could act in psoriasis and other immune-mediated diseases, reinforcing the rationale for its clinical development as a potential oral option for mild-to-moderate psoriasis patients seeking safer, better-tolerated therapies. The research, conducted with UK and Norwegian partners and partially grant-funded, strengthens Arctic Bioscience’s positioning in inflammation-targeted dermatology and supports continued investment in its R&D pipeline. **More about Arctic Bioscience AS** Arctic Bioscience is a biotech company focused on developing and commercializing pharmaceutical and nutraceutical products derived from bioactive marine compounds, particularly herring roe oil. Its lead drug candidate, HRO350, is an oral treatment in development for patients with mild-to-moderate psoriasis, while its nutraceutical offerings are sold globally as bulk ingredients and finished products under the ROMEGA brand. **Average Trading Volume:** 16,099 **Current Market Cap:** NOK91.11M Find detailed analytics on 9TD stock on TipRanks’ Stock Analysis page. ### Related Stocks - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [CRBU.US](https://longbridge.com/en/quote/CRBU.US.md) - [ASMB.US](https://longbridge.com/en/quote/ASMB.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ZIVO.US](https://longbridge.com/en/quote/ZIVO.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) ## Related News & Research - [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md) - [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md) - [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md) - [EverGen Infrastructure Reports Q2 2026 Results | EVGIF Stock News](https://longbridge.com/en/news/297122882.md) - [Biotech Stocks Facing FDA Decision In September 2026](https://longbridge.com/en/news/297065559.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**